Literature DB >> 3580254

Evidence for polymorphic oxidation of sparteine in Japanese subjects.

T Ishizaki, M Eichelbaum, Y Horai, K Hashimoto, K Chiba, H J Dengler.   

Abstract

The metabolism of sparteine which exhibits a genetic polymorphism in Caucasians was studied in 84 unrelated Japanese subjects. In contrast to a recent study where debrisoquine was used as a probe and no poor metabolizers could be observed in Japanese involving 100 subjects, two subjects had a urinary metabolic ratio of sparteine greater than 20 and thus were poor metabolizers of sparteine. The incidence of poor metabolizer phenotype of sparteine oxidation of 2% seems to be lower in Japanese as compared with various Caucasian populations where 5 to 10% are poor metabolizers of sparteine. However, this is not conclusive, because the 95% confidence interval of the observed frequency, 0.6 to 8%, covers the range reported in the literature for Caucasians.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3580254      PMCID: PMC1386100          DOI: 10.1111/j.1365-2125.1987.tb03080.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  15 in total

1.  Dissociation of co-regulatory control of debrisoquin/phenformin and sparteine oxidation in Ghanaians.

Authors:  N M Woolhouse; M Eichelbaum; N S Oates; J R Idle; R L Smith
Journal:  Clin Pharmacol Ther       Date:  1985-05       Impact factor: 6.875

Review 2.  Defective oxidation of drugs: pharmacokinetic and therapeutic implications.

Authors:  M Eichelbaum
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

3.  Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities.

Authors:  M Eichelbaum; L Bertilsson; J Säwe; C Zekorn
Journal:  Clin Pharmacol Ther       Date:  1982-02       Impact factor: 6.875

4.  Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine.

Authors:  L Bertilsson; H J Dengler; M Eichelbaum; H U Schulz
Journal:  Eur J Clin Pharmacol       Date:  1980-02       Impact factor: 2.953

5.  Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.

Authors:  M Eichelbaum; N Spannbrucker; B Steincke; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

6.  Polymorphic drug oxidation in humans.

Authors:  M Eichelbaum
Journal:  Fed Proc       Date:  1984-05-15

7.  The genetic control of sparteine and debrisoquine metabolism in man with new methods of analysing bimodal distributions.

Authors:  D A Evans; D Harmer; D Y Downham; E J Whibley; J R Idle; J Ritchie; R L Smith
Journal:  J Med Genet       Date:  1983-10       Impact factor: 6.318

8.  Deficient metabolism of debrisoquine and sparteine.

Authors:  T Inaba; S V Otton; W Kalow
Journal:  Clin Pharmacol Ther       Date:  1980-04       Impact factor: 6.875

9.  Inter-ethnic difference in sparteine oxidation among Ghanaians and Germans.

Authors:  M Eichelbaum; N M Woolhouse
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

10.  Sparteine metabolism in Canadian Caucasians.

Authors:  A Vinks; T Inaba; S V Otton; W Kalow
Journal:  Clin Pharmacol Ther       Date:  1982-01       Impact factor: 6.875

View more
  13 in total

1.  Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine.

Authors:  I Johansson; Q Y Yue; M L Dahl; M Heim; J Säwe; L Bertilsson; U A Meyer; F Sjöqvist; M Ingelman-Sundberg
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Japanese population.

Authors:  Y Horai; J Taga; T Ishizaki; K Ishikawa
Journal:  Br J Clin Pharmacol       Date:  1990-01       Impact factor: 4.335

Review 3.  Genetic polymorphism of drug metabolizing enzymes: new mutations in CYP2D6 and CYP2A6 genes in Japanese.

Authors:  T Yokoi; T Kamataki
Journal:  Pharm Res       Date:  1998-04       Impact factor: 4.200

4.  The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine.

Authors:  Junichi Azuma; Tomoko Hasunuma; Masanori Kubo; Masaya Miyatake; Toshiko Koue; Koushi Higashi; Tsutomu Fujiwara; Sachiko Kitahara; Tamiki Katano; Sumiko Hara
Journal:  Eur J Clin Pharmacol       Date:  2011-07-08       Impact factor: 2.953

5.  Apparent mendelian recessive inheritance of sparteine metabolism in an extended Japanese family.

Authors:  K Chiba; J Kato; K Hashimoto; T Ishizaki
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

6.  Metoprolol oxidation in a Japanese population: evidence for only one poor metaboliser among 262 subjects.

Authors:  Y Horai; T Ishizaki; K Ishikawa
Journal:  Br J Clin Pharmacol       Date:  1988-12       Impact factor: 4.335

7.  Genetically determined sparteine oxidation polymorphism in a Polish population.

Authors:  K Orzechowska-Juzwenko; J Pawlik; P Niewiński; P Milejski; J Dembowski; J Turek; A Goździk; L Swiebodzki; Z Hora
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

8.  Genetically determined N-acetylation and oxidation capacities in Japanese patients with non-occupational urinary bladder cancer.

Authors:  Y Horai; K Fujita; T Ishizaki
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

9.  The metabolism of aprindine in relation to the sparteine/debrisoquine polymorphism.

Authors:  T Ebner; M Eichelbaum
Journal:  Br J Clin Pharmacol       Date:  1993-04       Impact factor: 4.335

10.  N-acetylation phenotyping with dapsone in a mainland Chinese population.

Authors:  Y Horai; H H Zhou; L M Zhang; T Ishizaki
Journal:  Br J Clin Pharmacol       Date:  1988-01       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.